-+ 0.00%
-+ 0.00%
-+ 0.00%
Sonoma Pharmaceuticals FY26 net loss narrows to $3.18 million; revenue rises 37% to $19.53 million
Share
Listen to the news
Sonoma Pharmaceuticals FY26 net loss narrows to $3.18 million; revenue rises 37% to $19.53 million
  • Sonoma Pharmaceuticals posted a net loss of USD 3.18 million; loss per share narrowed to USD 1.89.
  • Revenue rose 37% to USD 19.53 million; U.S. revenue more than doubled to USD 5.67 million.
  • Gross profit increased 36% to USD 7.42 million; gross margin was unchanged at 38%.
  • R&D expense climbed 25% to USD 2.27 million, due to increased product development to support new product releases.
  • Cash and cash equivalents fell to USD 2.4 million; operating cash outflow widened to USD 3.93 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sonoma Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-004871), on June 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending